Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topoisomerase I interactive agents.

P Kellie Turner1, Lisa C Iacono, Clinton F Stewart

  • 1Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.

Cancer Chemotherapy and Biological Response Modifiers
|September 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Clinical pharmacokinetics·2026
Same author

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Neuro-oncology pediatrics·2026
Same author

Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer.

Clinical pharmacology and therapeutics·2026
Same author

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.

Cephalalgia : an international journal of headache·2025
Same author

Quantitative determination of Selinexor concentrations in plasma samples from children with non-rhabdomyosarcoma soft-tissue sarcomas: Troubleshooting plasma instability issues.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2025
Same author

Comparison of GFR estimation equations using creatinine, cystatin C, and their combination in pediatric hematology-oncology: no single equation is superior across subgroups.

Pediatric nephrology (Berlin, Germany)·2025
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Understanding topoisomerase I agents is key to improving cancer therapy. Research focuses on mechanisms, overcoming resistance, and optimizing dosing for better antitumor activity and reduced toxicity.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Topoisomerase I interactive agents are crucial in cancer therapy.
  • Maximizing their therapeutic index requires deeper mechanistic insight.

Purpose of the Study:

  • Elucidate mechanisms of cell death induced by topoisomerase I agents.
  • Investigate and circumvent ABC transporter-mediated resistance.
  • Optimize dosing strategies for enhanced antitumor activity and reduced toxicity.

Main Methods:

  • Preclinical studies to understand drug-induced cell death.
  • Research into the role of ABC transporters in drug resistance.
  • Translational research linking preclinical findings to clinical trial design.

Related Experiment Videos

Main Results:

  • Protracted dosing of topoisomerase I agents shows enhanced antitumor activity.
  • Clinical trials are beginning to support preclinical dosing observations.
  • Understanding dose-limiting toxicities is crucial for optimal agent use.

Conclusions:

  • Further research into topoisomerase I agent mechanisms is essential.
  • Overcoming drug resistance and optimizing dosing will improve therapeutic outcomes.
  • Ongoing development of new topoisomerase I agents offers future therapeutic potential.